Helix BioPharma (OTCMKTS:HBPCF – Get Free Report) and CorMedix (NASDAQ:CRMD – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, valuation, profitability and dividends.
Risk & Volatility
Helix BioPharma has a beta of -0.01, suggesting that its stock price is 101% less volatile than the S&P 500. Comparatively, CorMedix has a beta of 1.57, suggesting that its stock price is 57% more volatile than the S&P 500.
Profitability
This table compares Helix BioPharma and CorMedix’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Helix BioPharma | N/A | N/A | -1,097.76% |
| CorMedix | N/A | -79.21% | -64.68% |
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Helix BioPharma | 0 | 0 | 0 | 0 | 0.00 |
| CorMedix | 0 | 0 | 6 | 0 | 3.00 |
CorMedix has a consensus target price of $15.67, indicating a potential upside of 49.21%. Given CorMedix’s stronger consensus rating and higher possible upside, analysts clearly believe CorMedix is more favorable than Helix BioPharma.
Earnings and Valuation
This table compares Helix BioPharma and CorMedix”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Helix BioPharma | N/A | N/A | -$6.82 million | ($0.10) | -4.55 |
| CorMedix | $60,000.00 | 10,619.00 | -$46.34 million | ($0.81) | -12.96 |
Helix BioPharma has higher earnings, but lower revenue than CorMedix. CorMedix is trading at a lower price-to-earnings ratio than Helix BioPharma, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
34.2% of CorMedix shares are held by institutional investors. 7.6% of Helix BioPharma shares are held by company insiders. Comparatively, 5.2% of CorMedix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
CorMedix beats Helix BioPharma on 7 of the 12 factors compared between the two stocks.
About Helix BioPharma
Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada.
About CorMedix
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
Receive News & Ratings for Helix BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helix BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
